CAMKIIδ Reinforces Lipid Metabolism and Promotes the Development of B Cell Lymphoma
Advanced Science · 2025
DOI: 10.1002/advs.202409513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jiawei Zhang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), Second Affiliated Hospital, School of …. Hauptthemen laut MEDLINE: Calcium-Calmodulin-Dependent Protein Kinase Type 2, Lipid Metabolism, Lymphoma, B-Cell. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
The most prevalent types of lymphomas are B cell lymphomas (BCL). Newer therapies for BCL have improved the prognosis for many patients. However, approximately 30% with aggressive BCL either remain refractory or ultimately relapse. These patients urgently need other options. This study shows how calcium/calmodulin‐dependent protein kinase II delta (CAMKIIδ) is pivotal for BCL development. In BCL cells, ablation of CAMKIIδ inhibits both lipolysis from lipid droplets and oxidative phosphorylation (OXPHOS). With lipolysis blocked, BCL progression is markedly suppressed in two distinct BCL mouse models: MYC‐driven EµMyc mice and Myc/Bcl2 double‐expressed mice. When CAMKIIδ is present, it destabilizes transcription factor Forkhead Box O3A (FOXO3A) by phosphorylating it at Ser7 and Ser12. This then permits transcription of downstream gene IRF4 – a master transcription factor of lipid metabolism. The CAMKIIδ/FOXO3A axis bolsters lipid metabolism, mitochondrial respiration, and tumor fitness in BCL under metabolic stress. This study also evaluates Tetrandrine (TET), a small molecule compound, as a potent CAMKIIδ inhibitor. TET attenuates metabolic fitness and elicits therapeutic responses both in vitro and in vivo. Collectively, this study highlights how CAMKIIδ is critical in BCL progression. The results also pave the way for innovative therapeutic strategies for treating aggressive BCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.
- Molecular and Cellular Biology of Cancer Program & Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, 91010,…
- Center for Genetic Medicine, the Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, 322000, China.
- Institute of Genetics, International School of Medicine, Zhejiang University, Hangzhou, 310058, China.
- Department of Digestive, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, 350001, China.
- Integrative Genomic Core, City of Hope National Medical Center, Duarte, CA, 91010, USA.
ORCID-Profile: Ying Gu
Förderung
- National Natural Science Foundation of China
- NCI NIH HHS
- NIH HHS
- National Cancer Institute of the National Institutes of Health
- Natural Science Foundation of Zhejiang Province
- National Institutes of Health
Zitieren
APA
Zhang, J., Xu, S., Fang, H., Wu, D., Ouyang, C., Shi, Y., Hu, Z., Zhang, M., Zhong, Y., Zhao, J., Gan, Y., Zhang, S., Liu, X., Yin, J., Li, Y., Tang, M., Wang, Y., Li, L., Chan, W. C., …, & Gu, Y. (2025). CAMKIIδ Reinforces Lipid Metabolism and Promotes the Development of B Cell Lymphoma. Advanced Science. https://doi.org/10.1002/advs.202409513
Vancouver
Zhang J, Xu S, Fang H, Wu D, Ouyang C, Shi Y, et al. CAMKIIδ Reinforces Lipid Metabolism and Promotes the Development of B Cell Lymphoma. Advanced Science. 2025. doi:10.1002/advs.202409513
BibTeX
@article{Zhang2025,
author = {Zhang, Jiawei and Xu, Senlin and Fang, Hui and Wu, Dehao and Ouyang, Ching and Shi, Yunfei and Hu, Zhenkang and Zhang, Mingfeng and Zhong, Yaoyao and Zhao, Junwei and Gan, Yichao and Zhang, Shize and Liu, Xiaoqian and Yin, Jie and Li, Yuan and Tang, Mengyue and Wang, Yingda and Li, Ling and Chan, Wing C and Horne, David and Feng, Mingye and Huang, Wendong and Gu, Ying},
title = {CAMKIIδ Reinforces Lipid Metabolism and Promotes the Development of B Cell Lymphoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202409513}
}
EUVIMED